[EN] ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM [FR] N-SULFONYLGLYCINAMIDES ALPHA-SUBSTITUÉS ANTAGONISTES DU CCR10, COMPOSITIONS LES CONTENANT, ET LEURS PROCÉDÉS D'UTILISATION
ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM
申请人:Cogan Derek
公开号:US20110275612A1
公开(公告)日:2011-11-10
Disclosed is a compound of formula (I). Wherein R
1
, R
2
Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.
Alpha-substituted N-sulfonyl gylcine amides antagonists of CCR10, compositions containing the same and methods for using them
申请人:Cogan Derek
公开号:US08859814B2
公开(公告)日:2014-10-14
Disclosed is a compound of formula (I). Wherein R1, R2Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.
[EN] ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM<br/>[FR] N-SULFONYLGLYCINAMIDES ALPHA-SUBSTITUÉS ANTAGONISTES DU CCR10, COMPOSITIONS LES CONTENANT, ET LEURS PROCÉDÉS D'UTILISATION
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2009142984A1
公开(公告)日:2009-11-26
Disclosed is a compound of formula (I). Wherein R1, R2 Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.